Frankfurt, Germany?Twenty-three gauge vitrectomy instrumentation has become available and offers surgeons an alternative to 25-gauge instruments. Claus Eckardt, MD, looked at the pros and cons of these smaller instruments.
Cleveland?Gene therapy and pharmacologic therapy, administered separately and combined, rescued retinal function in blind mice that were bred without an enzyme crucial to the detection of light.
Atlanta?A 6-year study confirms the safety of dual-laser blepharoplasty for aesthetic rejuvenation of the upper and lower eyelids. Describing a series of 320 blepharoplasties, Harley Freiberger, MD, a dermatologic cosmetic surgeon in Los Angeles, reported that no permanent complications were observed, and that lesions healed rapidly and patients were quickly able to return to normal activity.
Des Plaines, IL?Addition Technology announces its fourth-quarter 2005 sales of Intacs corneal implants increased 29% over the same quarter the prior year and 12% over third-quarter 2005.
Glendora, CA?OASIS Medical filed a lawsuit against Johnson & Johnson/Johnson & Johnson Vision Care Inc. (J&J) in the U.S. District Court in the Central District of California, alleging that the companies' use of the name OASYS infringes and dilutes OASIS Medical's trademark rights. Acuvue Oasys with Hydraclear Plus is a trademark of Johnson & Johnson Vision Care Inc. for its line of Acuvue contact lenses.
Baltimore?Cataract surgeons and their patients now have three multifocal IOLs to choose from, depending on the patient's needs and interests as well as the physician's preference for and experience with a particular lens.
Early experience with corneal implants (Intacs, Addition Technology) to treat corneal ectasia including keratoconus, pellucid marginal degeneration, and post-LASIK ectasia, seems promising, according to Audrey Talley-Rostov, MD.
Lamellar keratoplasty (LK) performed with the femtosecond laser showed good early results and the development of few complications, according to Saj Khan, MD.